Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma

Steven Attia; Scott H. Okuno; Steven I. Robinson; Nicholas P. Webber; Daniel J. Indelicato; Robin L. Jones; Sanjay P. Bagaria; Courtney Sherman; Kevin R. Kozak; Cherise M. Cortese; Thomas McFarland; Jonathan C. Trent; Robert G. Maki

doi:10.4081/rt.2015.5992

Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma

Steven Attia, Scott H. Okuno, Steven I. Robinson, Nicholas P. Webber, Daniel J. Indelicato, Robin L. Jones, Sanjay P. Bagaria, Courtney Sherman, Kevin R. Kozak, Cherise M. Cortese, Thomas McFarland, Jonathan C. Trent, Robert G. Maki

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

We report a response to pazopanib in a 69- year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

Original language	English (US)
Article number	5992
Pages (from-to)	86-88
Number of pages	3
Journal	Rare Tumors
Volume	7
Issue number	2
DOIs	https://doi.org/10.4081/rt.2015.5992
State	Published - 2015

Keywords

Ewing
Pazopanib
Sarcoma

ASJC Scopus subject areas

Histology
Oncology

Access to Document

10.4081/rt.2015.5992

Cite this

@article{b930630cbc9f4627a49192f4778a7558,

title = "Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma",

abstract = "We report a response to pazopanib in a 69- year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.",

keywords = "Ewing, Pazopanib, Sarcoma",

author = "Steven Attia and Okuno, {Scott H.} and Robinson, {Steven I.} and Webber, {Nicholas P.} and Indelicato, {Daniel J.} and Jones, {Robin L.} and Bagaria, {Sanjay P.} and Courtney Sherman and Kozak, {Kevin R.} and Cortese, {Cherise M.} and Thomas McFarland and Trent, {Jonathan C.} and Maki, {Robert G.}",

note = "Publisher Copyright: {\textcopyright} S. Attia et al., 2015",

year = "2015",

doi = "10.4081/rt.2015.5992",

language = "English (US)",

volume = "7",

pages = "86--88",

journal = "Rare Tumors",

issn = "2036-3605",

publisher = "PagePress",

number = "2",

}

TY - JOUR

T1 - Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma

AU - Attia, Steven

AU - Okuno, Scott H.

AU - Robinson, Steven I.

AU - Webber, Nicholas P.

AU - Indelicato, Daniel J.

AU - Jones, Robin L.

AU - Bagaria, Sanjay P.

AU - Sherman, Courtney

AU - Kozak, Kevin R.

AU - Cortese, Cherise M.

AU - McFarland, Thomas

AU - Trent, Jonathan C.

AU - Maki, Robert G.

N1 - Publisher Copyright: © S. Attia et al., 2015

PY - 2015

Y1 - 2015

N2 - We report a response to pazopanib in a 69- year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

AB - We report a response to pazopanib in a 69- year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

KW - Ewing

KW - Pazopanib

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84930938424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930938424&partnerID=8YFLogxK

U2 - 10.4081/rt.2015.5992

DO - 10.4081/rt.2015.5992

M3 - Article

AN - SCOPUS:84930938424

SN - 2036-3605

VL - 7

SP - 86

EP - 88

JO - Rare Tumors

JF - Rare Tumors

IS - 2

M1 - 5992

ER -

Clinical activity of pazopanib in metastatic extraosseous ewing sarcoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this